These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 2523113)

  • 1. Basis for differing biological immunosuppressive potencies of monoclonal and polyclonal T cell antibodies.
    Sherburne CG; Condie RM; Onyekaba CO
    Transplant Proc; 1989 Feb; 21(1 Pt 1):1036-9. PubMed ID: 2523113
    [No Abstract]   [Full Text] [Related]  

  • 2. The use of an anti-CD3 priming dose to enhance the immunosuppressive potency of monoclonal and polyclonal T-cell antisera.
    Sherburne CG; Onyekaba CO; Condie RM
    Transplant Proc; 1991 Feb; 23(1 Pt 1):626-9. PubMed ID: 1824996
    [No Abstract]   [Full Text] [Related]  

  • 3. Suppression of the humoral response to anti-CD3 mAB by pretreatment with anti-CD4 mAB.
    Hirsch R; Chatenoud L; Gress RE; Bach JF; Sachs DH; Bluestone JA
    Transplant Proc; 1989 Feb; 21(1 Pt 1):1015-6. PubMed ID: 2523111
    [No Abstract]   [Full Text] [Related]  

  • 4. In vivo T lymphocyte activation induced in mice following the injection of anti-CD3 monoclonal antibody.
    Ferran C; Bluestone J; Bach JF; Chatenoud L
    Transplant Proc; 1990 Aug; 22(4):1922-3. PubMed ID: 2143865
    [No Abstract]   [Full Text] [Related]  

  • 5. Dose-dependent activation of murine T cells following in vivo administration of anti-murine CD3.
    Ellenhorn JD; Hirsch R; Hartley JP; Bluestone JA
    Transplant Proc; 1989 Feb; 21(1 Pt 1):1013-4. PubMed ID: 2523110
    [No Abstract]   [Full Text] [Related]  

  • 6. Analysis of the immunoregulatory capacity of anti-alpha/beta-TCR and anti-CD3 monoclonal antibodies.
    Kurrle R; Schorlemmer HU; Shearman C; Lauffer L; Frank K; Kanzy EJ; Seiler FR
    Transplant Proc; 1991 Feb; 23(1 Pt 1):272-6. PubMed ID: 1824982
    [No Abstract]   [Full Text] [Related]  

  • 7. Advantages of F(ab')2 fragments of anti-CD3 monoclonal antibody as compared to whole antibody as immunosuppressive agents in mice.
    Hirsch R; Bluestone JA; Bare CV; Gress RE
    Transplant Proc; 1991 Feb; 23(1 Pt 1):270-1. PubMed ID: 1824981
    [No Abstract]   [Full Text] [Related]  

  • 8. Acute toxicity of anti-CD3 monoclonal antibody in mice: a model for OKT3 first dose reactions.
    Alegre M; Depierreux M; Florquin S; Najdovski T; Vandenabeele P; Abramowicz D; Leo O; Deschodt-Lanckman M; Goldman M
    Transplant Proc; 1990 Aug; 22(4):1920-1. PubMed ID: 2143864
    [No Abstract]   [Full Text] [Related]  

  • 9. In vivo immunosuppressive effects of monoclonal antibodies specific for CD3+, CD4+, CD8+, and MHC class II positive cells.
    Stevens HP; Roche N; Hovius SE; Jonker M
    Transplant Proc; 1990 Aug; 22(4):1783-4. PubMed ID: 2143861
    [No Abstract]   [Full Text] [Related]  

  • 10. Cross-linking of Lyt-2 (CD8) to the T cell antigen receptor optimally activates T lymphocytes.
    Boyce NW; Eichmann K
    Transplant Proc; 1989 Feb; 21(1 Pt 1):133-7. PubMed ID: 2495596
    [No Abstract]   [Full Text] [Related]  

  • 11. RIV-9: a mouse IgG3 anti-human CD3 monoclonal antibody with strong antigen modulating and T cell eliminating properties.
    Vaessen LM; Kreeftenberg JG; Heyse P; Leerling MF; Baumgartner D; Hendriks GF; Jutte NH; Weimer W
    Transplant Proc; 1989 Feb; 21(1 Pt 1):1026-7. PubMed ID: 2523112
    [No Abstract]   [Full Text] [Related]  

  • 12. Degree of modulation of cell-surface CD3 by anti-lymphocyte therapies.
    Henell KR; Bakke A; Kenny TA; Kimball JA; Barry JM; Norman DJ
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1070-1. PubMed ID: 1824886
    [No Abstract]   [Full Text] [Related]  

  • 13. The human antimouse reaction to OKT3: cross-reactive pattern analysis using a large group of anti-CD3 and isotypic monoclonal antibodies.
    Shield CF; Hughes JD; Marlett P; Norman DJ
    Transplant Proc; 1989 Feb; 21(1 Pt 1):981-4. PubMed ID: 2523156
    [No Abstract]   [Full Text] [Related]  

  • 14. Different modes of T-cell activation by monoclonal antibodies to the alpha/beta T-cell receptor and the CD3 complex.
    Schlitt HJ; Schwinzer R; Wonigeit K
    Transplant Proc; 1989 Feb; 21(1 Pt 1):147-8. PubMed ID: 2523121
    [No Abstract]   [Full Text] [Related]  

  • 15. An overview of the use of the monoclonal antibody OKT3 in renal transplantation.
    Norman DJ
    Transplant Proc; 1988 Dec; 20(6):1248-52. PubMed ID: 2974204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reactivity of patient antisera to OKT3 with a panel of CD3 monoclonal antibodies.
    Nashan B; Schwinzer R; Wonigeit K; Pichlmayr R
    Transplant Proc; 1989 Feb; 21(1 Pt 1):985-6. PubMed ID: 2523157
    [No Abstract]   [Full Text] [Related]  

  • 17. In situ antigenic modulation of human graft-infiltrating T cells is induced by OKT3 treatment.
    Caillat-Zucman S; Legendre C; Noel LH; Bach JF; Kreis H; Chatenoud L
    Transplant Proc; 1990 Aug; 22(4):1782. PubMed ID: 2143860
    [No Abstract]   [Full Text] [Related]  

  • 18. Combined anti-CD2 and anti-CD3 receptor monoclonal antibodies induce donor-specific tolerance in a cardiac transplant model.
    Chavin KD; Qin L; Lin J; Yagita H; Bromberg JS
    J Immunol; 1993 Dec; 151(12):7249-59. PubMed ID: 7903105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of in vivo administration of anti-T3 monoclonal antibody on T cell function in mice. I. Immunosuppression of transplantation responses.
    Hirsch R; Eckhaus M; Auchincloss H; Sachs DH; Bluestone JA
    J Immunol; 1988 Jun; 140(11):3766-72. PubMed ID: 3286764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of I region-restricted, antigen-specific T cell hybridomas to produce idiotypically specific anti-receptor antibodies.
    White J; Haskins KM; Marrack P; Kappler J
    J Immunol; 1983 Mar; 130(3):1033-7. PubMed ID: 6185566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.